STT-5058
/ Staten Biotech, argenx
- LARVOL DELTA
Home
Next
Prev
1 to 7
Of
7
Go to page
1
January 23, 2023
A First in Human Study of STT-5058, an Antibody That Binds ApoC3
(clinicaltrials.gov)
- P1 | N=93 | Terminated | Sponsor: Staten Biotechnology BV | Active, not recruiting ➔ Terminated; recruitment failure
Trial termination • Dyslipidemia • Hypertriglyceridemia
October 06, 2022
A First in Human Study of STT-5058, an Antibody That Binds ApoC3
(clinicaltrials.gov)
- P1 | N=93 | Active, not recruiting | Sponsor: Staten Biotechnology BV | Recruiting ➔ Active, not recruiting
Enrollment closed • Dyslipidemia • Hypertriglyceridemia
June 21, 2022
A First in Human Study of STT-5058, an Antibody That Binds ApoC3
(clinicaltrials.gov)
- P1 | N=104 | Recruiting | Sponsor: Staten Biotechnology BV | Trial completion date: Jul 2022 ➔ Oct 2022 | Trial primary completion date: Jul 2022 ➔ Oct 2022
Trial completion date • Trial primary completion date • Dyslipidemia • Hypertriglyceridemia
November 10, 2021
A First in Human Study of STT-5058, an Antibody That Binds ApoC3
(clinicaltrials.gov)
- P1; N=104; Recruiting; Sponsor: Staten Biotechnology BV; Trial completion date: Oct 2021 ➔ Jul 2022; Trial primary completion date: Oct 2021 ➔ Jul 2022
Clinical • Trial completion date • Trial primary completion date • Dyslipidemia • Hypertriglyceridemia
August 18, 2021
A First in Human Study of STT-5058, an Antibody That Binds ApoC3
(clinicaltrials.gov)
- P1; N=104; Recruiting; Sponsor: Staten Biotechnology BV; Trial completion date: May 2021 ➔ Oct 2021; Trial primary completion date: May 2021 ➔ Oct 2021
Clinical • Trial completion date • Trial primary completion date • Dyslipidemia • Hypertriglyceridemia
June 11, 2020
A First in Human Study of STT-5058, an Antibody That Binds ApoC3
(clinicaltrials.gov)
- P1; N=104; Recruiting; Sponsor: Staten Biotechnology BV; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open • Dyslipidemia • Hypertriglyceridemia
June 05, 2020
A First in Human Study of STT-5058, an Antibody That Binds ApoC3
(clinicaltrials.gov)
- P1; N=104; Not yet recruiting; Sponsor: Staten Biotechnology BV
Clinical • New P1 trial • Dyslipidemia • Hypertriglyceridemia
1 to 7
Of
7
Go to page
1